Navigation Links
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
Date:7/17/2009

nology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of July 17, 2009 and expr
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
2. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
3. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
4. Amgen to Present at the Goldman Sachs Global Healthcare Conference
5. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
6. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
7. Amgen Highlights Data to Be Presented at ASCO
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
10. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
11. Amgen Announces Webcast of 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt ... at The Amazing Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at ... featured in media outlets as health authorities, and will present a two part seminar ...
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... a partnership agreement for quality market research promotion on the Internet. MarketPublishers.com ... Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager ...
Breaking Medicine News(10 mins):Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... and the Fastest Growing Healthcare Staffing Company with over 100 million Dollars ... ... Jackson Healthcare (JH) has been named the 5th largest healthcare staffing ... Compiled each year by SIA, firms are ranked on the list ...
... for their prolonged seizures with the sedative propofol may ... New research presented at CHEST 2008, the 74th annual ... Physicians (ACCP), shows that the use of propofol as ... (RSE), prolonged seizures that do not respond to initial ...
... look at the effect of neighborhood greenness on ... the Indiana University School of Medicine, Indiana University-Purdue ... that higher neighborhood greenness is associated with slower ... year period, regardless of residential density. , "Previous ...
... psychiatric cases in Michigan,s rural areas, particularly among children and ... colleges of Osteopathic Medicine and Human Medicine meet each week ... , On a typical morning, doctors in MSU,s Department of ... far away as Cadillac or Marquette all without leaving ...
... channel blockers could inhibit Plavix action, study says , , ... drugs, which are widely prescribed for coronary conditions, might ... new study says. , Calcium channel blockers appear to ... said the report by Austrian physicians published online Oct. ...
... Brachytherapy Treatment, ST. LOUIS, Oct. 27 ... to deliver radioactive seed therapy,in the prostate. The ... stabilizes the prostate during procedures. With the gland ... images to map,and confirm placement of radiation., ...
Cached Medicine News:Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 2Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 3Health News:Anti-seizure drug could be fatal 2Health News:Neighborhood greenness has long term positive impact on kids' health 2Health News:Neighborhood greenness has long term positive impact on kids' health 3Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, ... musculoskeletal healthcare, announced that it will be participating in ... at the Goldman Sachs offices in London ... About the Company Founded in 1927 and headquartered in ... a global leader in musculoskeletal healthcare.  We design, manufacture ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
... The Infinity Uric Acid single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Uric Acid reagent provides ...
... The Infinity Glucose Oxidase single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Glucose Oxidase reagent ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... provides a long shelf life that ...
... the profitability of your practice by seeing more ... VELO system you can turn a 14-18 patients ... day practice. By streamlining automated test sequences, youll ... technology is simple to learn; making it easy ...
Medicine Products: